Work with Us
Icahn School of Medicine at Mount Sinai: Research to Revenue

Icahn School of Medicine at Mount Sinai

Summit Venture Studio

Research to Revenue Report

Summit Venture Studio (SVS) Opportunities

SVS has identified 3 commercialization opportunities from Icahn School of Medicine at Mount Sinai and scored them based on our proprietary metrics and rubrics.
The SVS model is to identify the top 1% of commercialization opportunities and start companies around them.
Please connect with SVS if you would like to engage with us in our startup and investment efforts.

Return on Research (ROR) Analysis

Commercialization Revenue per Research Dollar

Top Universities by Return on Research (ROR)

ROI Ratio: Commercialization Revenue ÷ Research Funding

University Innovation Analysis

Total Innovation Scores by Institution

Top Universities by Innovation Score

180+ High Innovation
150-179 Strong Innovation
130-149 Moderate Innovation
100-129 Emerging Innovation

130+ total score considered high innovation impact

SVS Innovation Index

Proprietary Assessment of Icahn School of Medicine at Mount Sinai's Innovation Ecosystem
Score out of 100. Benchmark: Top 50 U.S. research institutions.
A score of 90/100 can be read "doing better than 90% of schools benchmarked"

Innovation Visibility

63/100
Definition: Media mentions, publication count, and global research visibility metrics

Startup Momentum

8/100
Definition: Growth in patents, funding, and startup formation

Ecosystem Strength

56/100
Definition: Tech transfer infrastructure and support systems

Innovation Legacy

A Timeline of Groundbreaking Discoveries

Innovation Timeline

Founded
1968
First Nobel
1980
First Patent
1991
First IPO
N/A
2022-2024
AI drug discovery
2025
Today

Notable Commercialization Outcomes

Nobel Prizes

5

1991
First Patent

Discovered HIV drug target

1991
Licensing Deal

Exclusive rights for cancer therapy

2005
Startup Launch

Spin-off for antibody technology

2010
Drug Approval

FDA approval for new drug

2015
Collaboration

Partnership on gene therapy

2018

Competitive Benchmarking

Icahn School of Medicine at Mount Sinai vs. Peer Research Universities

Icahn School of Medicine at Mount Sinai vs Peers Comparison

Metric Icahn School of Medicine at Mount Sinai (FY2023) Peer Average Elite Average
Annual R&D Expenditure $973M $855M $1,675M
New Inventions Disclosed 0 200 400
Startups Formed 4 7 10
Visibility Index 19 12 23
Licensing Revenue $15M $17M $46M
Note: Peer Average = Median value among U.S. R1 research universities. Elite Average = Top 10 ranked U.S. research universities.

Emerging Opportunities

1. Precision Immunotherapy Innovations Targeting Resistant Cancers
Advanced immunotherapies developed to overcome treatment resistance, addressing a critical unmet need in oncology with scalable, personalized medicine applications worldwide.
2. AI-Driven Predictive Models for Early Disease Diagnosis
Cutting-edge AI algorithms enable early detection of complex diseases, improving patient outcomes and reducing healthcare costs through scalable, data-driven solutions.
3. Novel Antiviral Therapies for Emerging Infectious Diseases
Breakthrough antiviral compounds address urgent global health threats with broad-spectrum potential, offering scalable treatment options amid rising infectious disease challenges.
4. Regenerative Medicine Using Stem Cell Technologies
Innovative stem cell therapies promote tissue repair and regeneration, meeting high-demand markets with scalable, transformative treatments for chronic conditions.
5. Digital Health Platforms Enhancing Chronic Disease Management
Integrated digital tools improve patient engagement and monitoring, providing scalable solutions that reduce complications and healthcare burdens in chronic disease care.
6. Neurodegenerative Disease Biomarkers for Early Intervention
Discovery of biomarkers enables early, accurate diagnosis of neurodegenerative disorders, facilitating timely treatment and scalable clinical applications to improve patient quality of life.
© 2025 Summit Venture Studio
Phone: (385) 351-4149